Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Breast Neoplasms 1

Interventions

ruxolitinib 28navitoclax 6Azacitidine 511-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 4parsaclisib 3luspatercept 3itacitinib 3givinostat hydrochloride 3givinostat 3fedratinib 3INCB039110 3selinexor 2pomalidomide 2imetelstat 2bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2INCB057643 2GRN163L peptide 2venetoclax 1triciribine 1tagraxofusp 1spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1rucaparib 1ridaforolimus 1quizartinib 1pelcitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Primary Myelofibrosis × Diagnosis × Clear all
NCT03121599 2020-08-11

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Hamad Medical Corporation

Phase NA Terminated
3 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡